Pimavanserin Treatment for Parkinson’s Disease Psychosis in Clinical Practice by Khashayar Dashtipour, Fiona Gupta, Robert A. Hauser, Cherian A. Karunapuzha, John C. Morgan

“…Pimavanserin is a newer atypical antipsychotic with highly selective binding to serotonergic receptors, no evidence for worsening motor symptoms in PD, and no need for white blood cell count monitoring. …”
Get full text

Sicca Symptoms in Parkinson’s Disease: Association with Other Nonmotor Symptoms and Health-Related Quality of Life by Tino Prell, Denise Schaller, Caroline Perner, Otto W. Witte, Julian Grosskreutz

“…Overall, 75% of the subjects took at least one drug that can cause sicca symptoms (anti-PD medication, antidepressant drugs, antihypertensive drugs, antipsychotic drugs, antimuscarinic drugs, and analgesic drugs). …”
Get full text

Hyponatremia due to preserved non-osmotic arginine vasopressin secretion in adipsic diabetes insipidus: a case report with review of literature by Yasufumi Seki, Shun Sugawara, Saya Suzuki, Yulia Minakuchi, Kazuhisa Kusuki, Yuzo Mizuno

“…Subsequent hyponatremia episodes occurred after administration of antipsychotic (124 mEq/L) and spontaneously (125 mEq/L) with unsuppressed plasma AVP levels (1.3 and 1.8 pg/mL, respectively). …”
Get full text

Sexual dysfunction among people with mental illness in Africa: A systematic review and meta-analysis study. by Setegn Fentahun, Mamaru Melkam, Gebresilassie Tadesse, Gidey Rtbey, Fantahun Andualem, Yilkal Abebaw Wassie, Gebremariam Wulie Geremew, Tekletsadik Tekleslassie Alemayehu, Tewodros Denekew Haile, Tilahun Nega Godana, Berihun Agegn Mengistie, Mulualem Kelebie, Girum Nakie, Techilo Tinsae, Girmaw Medfu Takelle

“…Having older age (OR = 1.92, 95% CI: 1.28, 2.87), longer duration of illness (OR = 2.60, 95% CI: 1.14, 5.93), history of relapse (OR = 3.51, 95% CI: 1.47, 8.43), poor quality of life (OR = 3.89, 95% CI: 2.15, 7.05), and antipsychotic medications (OR = 2.99, 95% CI: 1.84, 4.86) were significantly associated with sexual dysfunction.…”
Get full text

Digital sleep phenotype and wrist actigraphy in individuals at clinical high risk for psychosis and people with schizophrenia spectrum disorders: a systematic review and meta-analy... by Andrea Cipriani, Edoardo Giuseppe Ostinelli, John Torous, Paolo Brambilla, Philip McGuire, Dominic Oliver, Rosario Aronica, Charlotte Austin

“…TST results were inconclusive for CHR-P (MD −4.88 min (95% CI −20.57 to 10.81)), while SSD participants showed an increase in TST compared with HC (MD 106.13 min (86.02 to 124.24)). Factors such as antipsychotic medications (pseudo-R²=88.14%), age (38.89%) and gender (26.29%) partially explained the heterogeneity between subgroups. …”
Get full text

Suicidality and Illness Course Worsening in a Male Patient with Bipolar Disorder during Tamoxifen Treatment for ER+/HER2+ Breast Cancer by Claudia Carmassi, Francesco Pardini, Valerio Dell’Oste, Annalisa Cordone, Virginia Pedrinelli, Marly Simoncini, Liliana Dell’Osso

“…The clinical picture showed poor response to treatment trials based on various associations of mood-stabilising, antidepressants, and antipsychotic drugs. During the second hospitalization, after a multidisciplinary evaluation, the oncologists agreed on Tamoxifen discontinuation upon the severity of the psychiatric condition. …”
Get full text

Association Between GSK3β Gene Polymorphisms (rs334558 and rs3755557) with Schizophrenia Risk by Maryam Montazeri Dehbarez, Dormohammad Kordi Tamandani, Nasim Naeimi, Shahram Vaziri, Mohammad Shekari

“…Numerous studies have recognized GSK3ß as a gene associated with susceptibility to schizophrenia (SZ), highlighting its essential function in neurodevelopment and its potential as a target for antipsychotic medications. In this study, we examined the connection between two polymorphisms of the GSK3ß gene, rs334558 and rs3755557, and their potential link to the risk of schizophrenia. …”
Get full text

A Case of Violent Suicide Attempt in a Context of Myxedema Psychosis following Radioiodine Treatment in a Patient with Graves’ Disease by Louise Todorov, Amel Ait Boudaoud, Rachel Pascal de Raykeer, Alina Radu, Khadija Lahlou-Laforêt, Frédéric Limosin, Cédric Lemogne, Sébastien Czernichow

“…A rapid physical and psychiatric improvement was observed after the initiation of an oral thyroid replacement therapy without relapse after early discontinuation of the antipsychotic treatment. Discussion. The most distinctive feature of our case is that the violent suicide attempt could be attributed to the myxedema psychosis. …”
Get full text

Continuously relapsing (for two years) course of diarrheal variant of IBS (<i>Clinical case</i>) by Ye. A. Poluektova, S. Yu. Kuchumova, A. A. Kurbatova, A. A. Sheptulin, O. S. Shifrin, V. T. Ivashkin

“…Prescribed treatment included dioctaedric smectite, probiotic and antipsychotic drug, which had led to complete relief of all symptoms.Conclusion. …”
Get full text

Inequalities in physical comorbidity: a longitudinal comparative cohort study of people with severe mental illness in the UK by Tim Doran, Darren M Ashcroft, Evangelos Kontopantelis, David Reeves, Siobhan Reilly, Claire Planner, Ivan Olier, Linda Gask

“…We calculated the prevalence of SMI by UK country, English region and deprivation quintile, antipsychotic and antidepressant medication prescription rates for people with SMI, and prevalence rates of common comorbidities in people with SMI compared with people without SMI.Design Retrospective cohort study from 2000 to 2012.Setting 627 general practices contributing to the Clinical Practice Research Datalink, a UK primary care database.Participants Each identified case (346 551) was matched for age, sex and general practice with 5 randomly selected control cases (1 732 755) with no diagnosis of SMI in each yearly time point.Outcome measures Prevalence rates were calculated for 16 conditions.Results SMI rates were highest in Scotland and in more deprived areas. …”
Get full text

A False Case of Clozapine-Resistant Schizophrenia by J. P. Maia-de-Oliveira, J. P. Pinto, V. Alexandre, J. P. Machado-de-Sousa, S. L. Morais, C. Chaves, A. C. Sakamoto, A. W. Zuardi, J. A. S. Crippa, J. E. Hallak

“…About 30%–60% of schizophrenia patients do not respond adequately to antipsychotic treatment and are known as refractory schizophrenia patients. …”
Get full text

Factors Affecting Negative Symptoms in Schizophrenia and Their Relationship with Anxiety and Depression by Zeng G, Liang R, Xiao L, Cao W, Zhou W, Wang W, Liu C, Zhou H, Shi X, Chen B, Chen W

“…After adjusting for the duration of psychiatric disorder and type of antipsychotic medication as covariates, the above factors remained primary contributors to negative symptoms.Conclusion: Enhancing familial support, friend support, and addressing emotional health and sleep disturbances are strategies that may alleviate negative symptoms in patients with schizophrenia.Keywords: negative symptoms, anxiety, depression, schizophrenia, mental health…”
Get full text

A multidimensional assessment of adverse events associated with paliperidone palmitate: a real-world pharmacovigilance study using the FAERS and JADER databases by Siyu Lou, Zhiwei Cui, Yingyong Ou, Junyou Chen, Linmei Zhou, Ruizhen Zhao, Chengyu Zhu, Li Wang, Zhu Wu, Fan Zou

“…Abstract Objective Paliperidone palmitate is a second-generation antipsychotic that has undergone extensive investigation in clinical trials. …”
Get full text

Should we consider microbiota-based interventions as a novel therapeutic strategy for schizophrenia? A systematic review and meta-analysis by Lucas Hassib, Alexandre Kanashiro, João Francisco Cordeiro Pedrazzi, Bárbara Ferreira Vercesi, Sayuri Higa, Íris Arruda, Yago Soares, Adriana de Jesus de Souza, Alceu Afonso Jordão, Francisco Silveira Guimarães, Frederico Rogério Ferreira

“…Due to this multifactorial etiology and neurobiology, leading to a wide heterogeneity of symptoms and clinical presentations, current antipsychotic treatments face challenges, underscoring the need for novel therapeutic approaches. …”
Get full text

Establishment and Maintenance of a Digital Therapeutic Alliance in People Living With Negative Symptoms of Schizophrenia: Two Exploratory Single-Arm Studies by Cassandra Snipes, Cornelia Dorner‑Ciossek, Brendan D Hare, Olya Besedina, Tim Campellone, Mariya Petrova, Shaheen E Lakhan, Abhishek Pratap

“…MethodsTwo multicenter, exploratory, single-arm studies (study 1: CT-155-C-001 and study 2: CT-155-C-002) enrolled adults with schizophrenia and ENS receiving stable antipsychotic medication (≥12 weeks). Participants had access to CT-155 beta and were presented with daily in-app activities during a 3-week orientation phase that included lessons designed to facilitate building of a DWA. …”
Get full text

Impact of childhood trauma on cognitive function in patients with bipolar disorder by Zhiyang Zhang, Zhiyang Zhang, Chenyu Zhou, Chenyu Zhou, Zhen Mao, Zhen Mao, Yue Sun, Yue Sun, Lei Zhao, Lei Zhao, Tian Li, Tian Li, Chuanyue Wang, Chuanyue Wang, Qijing Bo, Qijing Bo

“…Mood stabilizer use was positively associated with language abilities, while antipsychotic use negatively impacted attention. Emotional abuse predicted impaired immediate memory, with the number of episodes and valproate dosage negatively correlating with total RBANS scores, whereas education and mood stabilizer use showed positive correlations.ConclusionsThe incidence of childhood trauma was higher among BD than HC, and different types of childhood trauma had varying effects on different aspects of cognition. …”
Get full text

Clozapine for Treatment-Resistant Disruptive Behaviors in Youths With Autism Spectrum Disorder Aged 10-17 Years: Protocol for an Open-Label Trial by André Luiz Schuh Teixeira da Rosa, Marina Ribeiro Barreto da Costa, Gabriela Bezerra Sorato, Felipe de Moura Manjabosco, Érica Bonganhi de Bem, Lucas Dellazari, Arthur Bezerra Falcão, Lucas de Oliveira Cia, Olivia Sorato Bezerra, Rogério Boff Borges, Luis Augusto Rohde, Ana Soledade Graeff-Martins

“…Clozapine, noted for its unique antiaggressive effects in schizophrenia and in various treatment-resistant neuropsychiatric disorders, independent from its antipsychotic efficacy, remains underexplored in youths with ASD facing severe and persistent DB. …”
Get full text

Parsing the heterogeneity of depression: a data-driven subgroup derived from cognitive function by Chenyang Xu, Yanbao Tao, Yunhan Lin, Jiahui Zhu, Zhuoran Li, Jiayi Li, Mingqia Wang, Tao Huang, Chuan Shi

“…Multiple regression analysis indicated that longer illness duration, lower educational levels, and antipsychotic medication use may be risk factors for cognitive impairment.ConclusionThis study identifies distinguishable cognitive subgroups in acute depression, thereby confirming the presence of cognitive heterogeneity. …”
Get full text

Shi-Zhen-An-Shen Decoction, a Herbal Medicine That Reverses Cuprizone-Induced Demyelination and Behavioral Deficits in Mice Independent of the Neuregulin-1 Pathway by Chao Ma, Yan Wu, Xinyao Liu, Yi He, Yuan Jia, Pei Chen, Dongqing Yin, Yanzhe Ning, Guoqiang Xing, Zuoli Sun, Hongxiao Jia

“…Sixty male C57BL/6 mice were randomly divided into six groups (n=10 per group): (1) control group, (2) cuprizone (CPZ, a copper chelator that induced demyelination, 0.2% w/w)+saline, (3) CPZ+low-dose SZASD (8.65 g·kg-1·d-1), (4) CPZ+medium-dose SZASD (17.29 g·kg-1·d-1), (5) CPZ+high-dose SZASD (25.94 g·kg-1·d-1), and (6) CPZ+quetiapine (QTP, an atypical antipsychotic that served as a positive treatment control, 10 mg·kg-1·d-1). …”
Get full text

The time has come for revising the rules of clozapine blood monitoring in Europe. A joint expert statement from the European Clozapine Task Force by Hélène Verdoux, Robert A. Bittner, Alkomiet Hasan, Mishal Qubad, Elias Wagner, Alexis Lepetit, Manuel Arrojo-Romero, Christian Bachmann, Marieke Beex-Oosterhuis, Jan Bogers, Andreja Celofiga, Dan Cohen, Domenico de Berardis, Marc de Hert, Carlos de Las Cuevas, Bjørn H. Ebdrup, Konstantinos N. Fountoulakis, Daniel Guinart, Dolores Keating, Miloslav Kopeček, John Lally, Judit Lazáry, Jurjen J. Luykx, Olalla Maronas Amigo, Espen Molden, Jimmi Nielsen, Brian O’Donoghue, Pierre Oswald, Flavian S. Radulescu, Christopher Rohde, Marina Sagud, Emilio J. Sanz, Ivona Šimunović Filipčić, Iris E. Sommer, Heidi Taipale, Jari Tiihonen, Heli Tuppurainen, Selene Veerman, Alina Wilkowska, Edoardo Spina, Peter Schulte

“…Although clozapine is the most effective antipsychotic for people with treatment-resistant schizophrenia, a large proportion of them do not have access to this treatment. …”
Get full text